岁末年终，让我们一起回顾高光时刻！ 01 更名启新程 战略谋长远 圣方医药研发更名为"太美智研医药"，明确了"AI驱动的医药研发解决方案提供商"核心定位，以太美创 新的基因，为创新药行业的发展持续贡献力量。 2025年终回顾 2025年 太美智研医药笃定前行、硕果盈枝 项目合作、行业研讨、科研成果、专业著作 多点开花 02 硬核支持临床运营 成果闪耀国际 全程助力由复旦大学附属中山医院樊嘉院士领衔的中国原创研究TALENTop肝细胞癌Ⅲ期研究，推动相 关研究成果于 2025 ESMO 大会全球首发，为肝癌治疗领域的技术突破与临床实践开辟全新方向。 03 专业医学支持 助力终点裁定 参与某知名药企Ⅲ期关键注册项目的CEC章程制定，组织潜在事件CEC会议，提供独立、专业裁定支 持； 04深耕药物警戒领域 护航药品全生命周期安全 为天士力普佑克脑梗适应症Ⅲ期临床试验提供药物安全风险管理服务，助力核心适应症获批； 组织撰写《AI 在药物警戒中的应用·专家共识(2025)》，为 AI 在药物警戒领域的应用提供参考； 参与翻译和出版《科伯特药物安全和药物警戒手册》，推动国际经验本土化。 05 强化数据科学与统计 加速创新 ...

Summary of Cencora (NYSE:COR) FY Conference Call - December 02, 2025 Company Overview - **Company**: Cencora - **Industry**: Healthcare Services, specifically focusing on pharmaceutical distribution and management services organizations (MSOs) Key Points and Arguments Financial Performance and Guidance - Cencora reported strong fourth-quarter results for fiscal year 2025, with guidance for fiscal year 2026 indicating 9%-11% operating income growth in the US segment [4][22] - Long-term guidance has been increased, reflecting confidence in the specialty market's growth [4][5] Acquisition Strategy - The acquisition of OneOncology is highlighted as a significant growth driver, with Cencora currently owning 35% and looking to acquire the remaining 65% [6][7] - The acquisition is expected to enhance operating income and create synergies between OneOncology and RCA, particularly in clinical trials [7][8] Specialty Market Focus - Cencora's strength lies in its leadership position in the specialty market, benefiting from sales to specialty physician practices and health systems [5][14] - The company is pursuing both organic and inorganic growth opportunities in oncology and retina markets, with a focus on acquiring smaller practices [15][16] Capital Deployment - Projected free cash flow of $15 billion-$20 billion by the end of the decade will be strategically deployed, with a significant portion earmarked for the acquisition of OneOncology [21][22] - Cencora plans to invest approximately $900 million in capital expenditures, primarily in infrastructure for its specialty business [21] International Segment Performance - The international segment, which includes Alliance and World Courier, is a significant contributor to operating income, with Alliance being the largest revenue source [24][27] - World Courier is expected to stabilize and grow as clinical trial activities pick up [29][30] Regulatory Environment and Drug Pricing - The company is actively engaging in discussions regarding the impact of regulatory changes, particularly around the Physician Fee Schedule and drug pricing negotiations under the IRA [33][41] - Cencora emphasizes the importance of maintaining access to pharmaceuticals and affordability for patients [46] Growth Drivers and Market Trends - Cencora anticipates a wave of generic launches and biosimilars, which will positively impact revenue, although the profit margins may differ from previous years due to contract rebalancing [54][57] - The company is focused on digital transformation and productivity improvements as part of its long-term strategy [76][79] Conclusion - Cencora is positioned for continued growth through strategic acquisitions, a strong focus on the specialty market, and effective capital deployment. The company aims to enhance its operational efficiency and maintain a strong value proposition in the healthcare supply chain [76][79]

Core Insights - The National Medical Products Administration (NMPA) held a drug vigilance work conference on October 22, 2023, in Shandong to summarize the achievements of drug vigilance efforts over the past year and to analyze the current situation for future planning [1] Group 1 - The conference focused on evaluating the effectiveness of drug vigilance work in China over the past year [1] - The meeting aimed to deeply analyze the current situation regarding drug safety and vigilance [1] - Future work arrangements and strategies for drug vigilance were discussed during the conference [1]

Core Viewpoint - The Hainan Provincial Drug Vigilance Center is enhancing collaboration and utilizing digital tools to improve risk monitoring and ensure medication safety for the public [1][2][3] Group 1: Risk Monitoring and Response - The center identified multiple adverse events related to a specific batch of disposable surgical gloves, indicating potential quality issues [2] - The center's primary responsibility includes monitoring and evaluating adverse reactions and events to mitigate potential safety risks [2][3] - Hainan's drug adverse reaction report total is slightly above the national average, while the center's staff is only one-third of the national average for provincial monitoring agencies, indicating a high workload [3] Group 2: Collaborative Efforts and Training - The center collaborates with the Provincial Health Commission to establish a coordinated assessment mechanism, integrating monitoring into the accountability system for medical institutions [4] - The number of monitoring points has been expanded, and specialized training for monitoring personnel is ongoing to enhance sensitivity in detecting risks [4] Group 3: Digital Tools and Innovations - The center is integrating risk signal identification and rapid reporting of adverse drug reactions into the Hainan "Three Medical Linkage One Network" platform [4][5] - This platform aims to eliminate data silos among departments, making risk monitoring more intelligent and convenient [5] Group 4: Unique Responsibilities and Advantages - Hainan's drug vigilance center has unique tasks due to special policies allowing early use of innovative medical devices not yet registered in China [5][6] - The center has established a comprehensive monitoring system for innovative medical devices used in the Boao Lecheng area, focusing on patient registration, clinical follow-up, and lifecycle traceability [6][7] - The center aims to leverage its policy advantages to enhance research capabilities and improve the drug vigilance system and risk management [7]

Group 1 - The report highlights that the pharmaceutical index has shown positive returns across most of the six sub-industries, indicating a strong performance in the sector [1][9]. - The draft of the "Best Practice Framework for AI in Pharmacovigilance" was released on May 1, aiming to guide the development and application of AI in monitoring adverse drug reactions. This technology is expected to bring revolutionary improvements to drug safety monitoring, although a risk-oriented regulatory and governance system is necessary [2][7]. - According to the "China Pharmacovigilance Industry Research Report," the Chinese pharmacovigilance market is experiencing significant growth, with 2.419 million adverse drug reaction reports filed in 2023, reflecting an improvement in monitoring capabilities [2][8]. Group 2 - The report notes that the global pharmacovigilance market was valued at 58.568 billion in 2022 and is projected to grow at a CAGR of 10.02%, reaching approximately 103.894 billion by 2028 [8]. - The report emphasizes that the domestic AI healthcare models are rapidly developing, and the pharmacovigilance industry is expected to continue its strong growth trajectory, necessitating the establishment of a comprehensive regulatory framework [8]. - The report indicates that the innovation drug sector is entering a harvest period, supported by strong policy backing and innovation-driven growth, which is expected to enhance the overall performance of the pharmaceutical sector [16][20].